Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesGenentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Genentech, 05/20/09
Genentech, Inc. and Biogen Idec announced that the companies submitted two supplemental Biologics License Applications to the U.S. Food and Drug Administration for Rituxan plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia. The companies will request a priority review, and if granted, anticipate the FDA will make a decision within six months.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi Pasteur obtains license from Syntiron to develop & commercialize vaccine to prevent Staphylococcus infections
Sanofi-aventis, 12/17/09
Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09
Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Generic drugs dominate market, look to expand into biologics
Formulary , 12/16/09
Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor